<?xml version="1.0" encoding="UTF-8"?>
<supplementary-material content-type="local-data">
 <p>Supplementary material for this article is available at 
  <ext-link ext-link-type="uri" xlink:href="http://advances.sciencemag.org/cgi/content/full/5/10/eaax4761/DC1" xmlns:xlink="http://www.w3.org/1999/xlink">http://advances.sciencemag.org/cgi/content/full/5/10/eaax4761/DC1</ext-link>
 </p>
 <p>Fig. S1. A microfluidic device containing cell-trapping microstructures for high-throughput analysis of single-cell infections.</p>
 <p>Fig. S2. Evaluation of 2′-
  <italic>C</italic>-Me-A, a PV RdRp inhibitor.
 </p>
 <p>Fig. S3. Translation of eGFP mRNA and activation of fluorophore are normal in the presence of GA and GS.</p>
 <p>Fig. S4 Evaluation of GS, an HSP90 inhibitor.</p>
 <p>Fig. S5 Evaluation of an antiviral drug combination: 2′-C-Me-A and GS.</p>
 <p>Fig. S6 Evaluation of inhibitor-specific signatures.</p>
 <p>Table S1. Means, SD, and 
  <italic>P</italic> values between groups for the 2′-
  <italic>C</italic>-Me-A experiment.
 </p>
 <p>Table S2. Means, SD, and 
  <italic>P</italic> values between groups for the rupintrivir experiment.
 </p>
 <p>Table S3. Means, SD, and 
  <italic>P</italic> values between groups for experiments with HSP90 inhibitors.
 </p>
 <p>Table S4. Means, SD, and 
  <italic>P</italic> values between groups for antiviral synergy experiments.
 </p>
</supplementary-material>
